Thermo Fisher Scientific, a leading entity in providing essential services to the biopharmaceutical sector, is significantly enhancing its technological capabilities by acquiring Clario, a prominent clinical trial software company, for $9 billion. This strategic move underscores Thermo Fisher’s commitment to advancing clinical trial operations and improving drug development processes.
In clinical trials, vast quantities of data are generated that require thorough analysis to inform decisions made by pharmaceutical and biotech companies. This critical data, known as clinical trial endpoint data, is essential for determining the next steps in the development pipeline. Clario’s advanced technology seamlessly integrates this data from various sources, including medical devices, clinical trial locations, and patient inputs, both during drug development and post-market. In its announcement on October 29 regarding the acquisition, Thermo Fisher emphasized that analyzing this data is vital for making informed decisions about research and development pipelines, regulatory compliance, and setting appropriate pricing and reimbursement strategies.
With a rich history dating back to the early 1970s, Clario has established itself as a leader in clinical trial data collection. The current iteration of Clario emerged from the 2021 merger between ERT (previously known as eResearch Technology) and Bioclinica, both of which were backed by private equity investments. The financial specifics of this merger were not publicly disclosed, but it marked a significant evolution in Clario’s capabilities and market presence.
Clario operates under the ownership of a consortium of investors led by Astorg, Nordic Capital, Novo Holding, and Cinven. The company boasts a workforce of around 4,000 employees spread across various global locations, with its technologies having facilitated clinical trials that have led to over 700 regulatory approvals. For the fiscal year 2025, Clario anticipates generating approximately $1.25 billion in revenue, although it has not disclosed whether the company is currently profitable.
Thermo Fisher’s primary involvement in clinical trial services comes through its acquisition of PPD, a contract research organization, for $21 billion four years ago. Additionally, Thermo Fisher offers contract manufacturing services via Patheon, which it acquired in 2017. The investment bank William Blair has characterized the Clario acquisition as “a home run,” reinforcing Thermo Fisher’s reputation as a preferred partner for the biopharma sector. In their investor communication, William Blair noted that Clario’s offerings are highly compatible with Thermo Fisher’s existing pharmaceutical services, particularly within the CRO segment. Analysts predict that Thermo Fisher will effectively utilize its established business connections to promote the adoption of Clario’s innovative products and services.
According to analysts, “Thermo’s acquisition of Clario enhances its platform for comprehensive endpoint data solutions compared to other leading CROs, creating significant opportunities for Thermo to cross-sell its CRO services alongside Clario’s endpoint data solutions to both new and existing biopharma sponsors.” This strategic positioning not only strengthens Thermo Fisher’s service portfolio but also enhances its competitive edge in the market.
Clario will be integrated into Thermo Fisher’s Laboratory Products and Biopharma Services division, which stands as the largest segment by revenue, having generated $23.1 billion in sales over the past year. This division is dedicated to providing essential products and services for laboratories, as well as outsourced services that pharmaceutical and biotechnology firms utilize during drug development and clinical trials. The most recent major acquisition in this segment was the purchase of CorEvitas in 2023, a company specializing in collecting real-world data concerning the safety and efficacy of pharmaceuticals.
Thermo Fisher and Clario anticipate finalizing the transaction by mid-2026. The financial structure of the deal includes $8.875 billion in cash payable at closing, with Thermo Fisher planning to finance the acquisition through a combination of debt financing and available cash reserves. Additionally, Clario’s shareholders are set to receive an extra $125 million in January 2027, with potential performance-based payouts of up to $400 million depending on Clario’s achievements in 2026 and 2027.
To stay updated on the latest trends in litigation, regulation, financial services, and business deals, consider signing up for Finance Docket, a collaborative initiative from Breaking Media publications, including Above the Law and Dealbreaker.
